In modern medicine many drugs and therapeutic approaches are available for the treatment of cancer. However, the disease often develops into an invasive metastatic form or recurs after years of remission. This may be attributed to cancer stem cells (CSCs), a small subset of cells with a tumorigenic potential that is resistant to most of therapeutic approaches. Thus, new therapeutic approaches effective, not only towards differentiated cancer cells, but also CSCs, are required. Lysosomal cysteine peptidases, cathepsin B and X that have important role in different processes of development and progression of cancer, could serve as promising molecular targets to improve CSCs-directed therapy.
First, we isolated cancer stem cells from three breast cancer cell lines MDA-MB-231, MCF7 and MCF-10A neoT, based on their ability to form tumorspheres, a characteristic that distinguishes CSCs from differentiated cells. For this purpose, we first determined the optimal conditions for tumorsphere formation. The most optimal medium for tumorsphere formation was DMEM/F-12 with serum free supplement for CSC growth B-27, and growth factors EGF and bFGF. Additionally, insulin and hydrocortisone were added for growth of MCF-10A neoT cells. Isolation of CSCs was confirmed by expression of cell surface markers and stem cell transcription factor SOX2. Following tumorsphere formation surface markers (CD44+/CD24–) and/or increased expression of SOX2 showed increase in cells with CSC phenotype.
Next, we demonstrated by western blot, ELISA and enzyme kinetics assay that protein levels and activity of cathepsin B were significantly increased in CSCs following tumorsphere formation compared to differentiated cells from all three cells lines. Similarly, protein levels and activity of cathepsin X were increased in CSCs from MDA-MB-231 and MCF7 cells, while CSCs from MCF-10A neoT cells showed only increased protein levels of cathepsin X, but not its activity.
Taken together, we showed that inhibition of cathepsin B and X in CSCs, using specific inhibitors, is a promising approach to increase the effectiveness of current antitumor therapies against CSCs and therefore to improve cancer treatment.
|